New Study shows Urolithin A (Mitopure®) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis
Amazentis, a spin-off of the Swiss Federal Institute of Technology (EPFL) pioneering scientific breakthroughs in cellular health and nutrition, announced today that the peer-reviewed journal Aging Cell published new pre-clinical results showing the joint health benefits of gut microbiome postbiotic Urolithin A (UA). This is the first time a compound has been shown to improve mitochondrial health in an experimental model of osteoarthritis (OA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220707005266/en/
(Photo: Amazentis)
This study showed that treatment with Amazentis’ proprietary Urolithin A, Mitopure, significantly improved mitochondrial health in human cartilage cells taken from both healthy and OA knee joints. And it showed that supplementation with Mitopure for eight weeks protected against osteoarthritis disease progression in an experimental model.
These findings highlight Mitopure’s benefits for joint and mitochondrial health. Mitopure works by supporting the cells’ ability to renew their powerplants, the mitochondria, during the aging process. This change is associated with age-related problems in various tissues, including osteoarthritis.
Previous research has shown Mitopure can improve mitochondrial health and muscle function in both older and middle-aged human populations. This new paper extends these benefits to cells in key joints such as the knee. Osteoarthritis is the most common age-related joint disorder, characterized by degradation of cartilage and other tissues, severe pain, and impaired mobility.
“There are currently no effective solutions to treat osteoarthritis, a condition that is painful and limits the mobility of hundreds of millions of older people around the world. We tested Urolithin A in preclinical models of osteoarthritis and showed it has potential to both reduce inflammation and improve mitochondrial health, suggesting it may be a promising solution to support joint health and quality of life during aging,” says Martin Lotz MD, lead author on the paper and Professor of Molecular Medicine at Scripps Research in California, USA.
“This study is important and exciting as it shows, for the first time, that Urolithin A can increase mitochondrial health in living joint tissue,” says Davide D’Amico, first author on the paper and R&D Group Leader with Amazentis. “It highlights the important role of mitophagy in maintaining healthy functioning joints throughout life.”
In this study, Mitopure showed two key beneficial effects on cartilage cells from both healthy donors and OA patients:
- It significantly induced the recycling of aged and damaged mitochondria (mitophagy), assessed by imaging and molecular biology assays.
- It significantly increased the activity of mitochondria, measured as mitochondrial respiration, i.e. the ability of these organelles to consume oxygen and produce energy for our cells.
The second part of the study focused on the effect of supplementing Mitopure for 2 months on an experimental pre-clinical model of osteoarthritis. This model mimics the same symptoms experienced by people suffering from osteoarthritis, i.e. progressive cartilage damage, increased pain and inflammation.
- Analysis of knee joint sections by a pathologist indicated that supplementation with Mitopure decreased joint tissue degradation.
- Mitopure supplementation also reduced OA associated leg pain and exerted a mild anti-inflammatory effect on the disease model.
- Finally, better joint heath after Mitopure administration was associated with significantly enhanced mitochondrial health, including higher rates of removing worn out mitochondria (mitophagy) and increased regeneration of new, functional mitochondria.
"It was great to collaborate with Scripps Research to expand the body of evidence on the health applications of Urolithin A into joint health. It’s exciting to see a compound and mechanism of action that is benefiting both muscle and joints. We remain committed to delivering products that are clinically proven to have a meaningful impact on people’s health” says Chris Rinsch, CEO and co-founder of Amazentis.
The new results are significant because they add to growing evidence of the benefits of Mitopure on age-related conditions. Recent studies showed that Mitopure can improve mitochondrial health and counteract age-related muscle function decline in both healthy elderly and middle-aged overweight subjects. Together, the latest research supports a combined beneficial action of Urolithin A in both muscle and joints.
Doi: 10.1111/acel.13662
About Amazentis
Amazentis is an innovative life sciences company employing today’s leading research and clinical science to develop the next generation of products targeting mitochondrial health for advanced nutrition. Amazentis has previously published its research on Mitopure® Urolithin A in top peer reviewed scientific journals including Nature Medicine (doi:10.1038/nm.4132), Nature Metabolism (doi: 10.1038/s42255-019-0073-4), JAMA Network Open (doi:10.1001/jamanetworkopen.2021.44279), Cell Reports Medicine
(Doi: 10.1016/j.xcrm.2022.100633) and European Journal of Clinical Nutrition (https://doi.org/10.1038/s41430-021-00950-1). The company has a global strategic partnership with Nestlé Health Science to expand the health applications of Mitopure® linked to mitochondrial and cellular health. For more information on Amazentis, please visit www.amazentis.com.
About Mitopure®
Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone. Mitopure® has been shown to improve mitochondrial function by stimulating mitophagy, a process by which aging and damaged mitochondria are cleared from the cell, making way for healthy mitochondria to grow. Mitopure® has been favorably reviewed by the U.S. Food and Drug Administration (FDA) and deemed safe following a GRAS (generally recognized as safe) filing. Mitopure® has been extensively evaluated pre-clinically and clinically to support its use in humans for nutritional supplementation. For more information, please visit www.mitopure.com.
About Timeline®
Timeline® is brought to you by the inventors of Mitopure®. This novel, science-first nutrition brand was developed by Amazentis on the belief that uncompromising research can unlock a new class of clinically validated nutritional products to optimize cellular health. For more information, please visit www.timelinenutrition.com.
Related Links
https://www.amazentis.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220707005266/en/
Contact information
Federico Luna
Chief Marketing Officer, Amazentis
press@amazentis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REI Super Selects SS&C For Superannuation Administration1.5.2025 06:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 04:25:00 EEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 20251.5.2025 04:00:00 EEST | Press release
GIGABYTE Technology, a global leader in computing innovation, will return to COMPUTEX 2025 from May 20 to 23 under the theme "Omnipresence of Computing: AI Forward." Demonstrating how GIGABYTE’s complete spectrum of solutions spanning the AI lifecycle, from data center training to edge deployment and end-user applications reshapes the infrastructure to meet the next-gen AI demands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428101781/en/ From Scalable Solutions to Full-Stack AI Infrastructure, GIGABYTE to Present End-to-End AI Portfolio at COMPUTEX 2025 As generative AI continues to evolve, so do the demands for handling massive token volumes, real-time data streaming, and high-throughput compute environments. GIGABYTE’s end-to-end portfolio - ranging from rack-scale infrastructure to servers, cooling systems, embedded platforms, and personal computing—forms the foundation to accelerate AI breakthroughs across industr
Carl Haney, Executive Vice President, Global Innovation and Research & Development to Depart The Estée Lauder Companies1.5.2025 01:00:00 EEST | Press release
Today, The Estée Lauder Companies Inc. (NYSE: EL) announced that Carl Haney, Executive Vice President, Global Innovation and Research & Development (R&D), will depart the company effective June 30, 2025 to pursue new opportunities. With Carl’s transition, the company intends to bring in new external talent to drive the next era of transformative innovation in line with its strategic vision of becoming the best, most consumer-centric, prestige beauty company in the world. “Over the past decade, Carl has forged impactful partnerships at the forefront of scientific innovation and delivered breakthrough products and superior formulations across categories, benefits and occasions, while fueling corporate innovation and advanced technologies,” said Stéphane de La Faverie, President and Chief Executive Officer, The Estée Lauder Companies. “As we look to the future and delivering our bold Beauty Reimagined vision, we will transform our approach to innovation across the company—which includes e
Clearwater Analytics Completes Acquisition of Beacon, Deepening Risk and Modeling Capabilities30.4.2025 23:15:00 EEST | Press release
Clearwater Analytics (NYSE: CWAN) (“Clearwater”), the most comprehensive technology platform for investment management, today announced it has completed its acquisition of Beacon Platform Inc. (Beacon), a provider of enterprise risk analytics and developer infrastructure. The acquisition strengthens Clearwater’s capabilities in complex portfolio management across both public and private markets, including structured products, private credit, and derivatives. For years, institutional investors have faced a tradeoff between advanced analytics and operational efficiency—navigating rigid legacy systems, endless manual processes, and disconnected data. These fragmented environments slow down decision-making, elevate risk, and obscure a clear, consolidated view of portfolios. Clearwater is changing that. With the integration of Beacon’s cross-asset risk modeling with front-office capabilities and alternative asset intelligence from the acquisitions of Enfusion, Inc. (Enfusion) and Blackstone
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom